Itacitinib is a potent orally selective JAK1 inhibitor with promising preliminary effectiveness in a phase 1 study including patients with corticosteroid refractory or corticosteroid naïve Graft-versus-host disease (GVHD) [144]. This evidence concerns the gene JAK1 and graft versus host disease.